Literature DB >> 18004079

Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma.

Tatsuya Rikimaru1, Akinobu Taketomi, Yo-ichi Yamashita, Ken Shirabe, Takayuki Hamatsu, Mitsuo Shimada, Yoshihiko Maehara.   

Abstract

OBJECTIVE: Histone deacetylases (HDACs) play an important role in chromatin remodeling, gene repression and regulating cell cycle progression and differentiation. This study was designed to clarify the role of HDAC1 expression in hepatocellular carcinoma (HCC).
METHOD: The expression of HDAC1 in 47 patients with surgically resected HCC was immunohistochemically examined and analyzed in relation to their clinicopathological factors. The patients were divided into two groups according to the expression status of HDAC1: a high HDAC1 group (n = 25) with more than 20% of positively stained cells and a low HDAC1 group (n = 22) with 20% or fewer positively stained cells.
RESULTS: A high HDAC1 expression indicated a higher incidence of cancer cell invasion into the portal vein, a poorer histological differentiation, and a more advanced TNM stage. The survival rates after a surgical resection in low and high HDAC1 patients at 1, 3, 5 and 10 years were 100, 95.5, 81.8 and 60.8% and 88.0, 60.0, 40.0 and 32.0%, respectively (p = 0.008). A multivariate analysis using the Cox regression analysis showed that a high HDAC1 expression was an independent prognostic factor of HCC in patients after hepatic resection (relative risk: 10.1, p = 0.0018).
CONCLUSIONS: High HDAC1 expression might have an important role in the aggressiveness and cell dedifferentiation, and its expression status may be a useful biomarker for predicting the outcome of the patients with HCC. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18004079     DOI: 10.1159/000111106

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  60 in total

1.  An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers.

Authors:  Terence K Lee; Saravana R K Murthy; Niamh X Cawley; Savita Dhanvantari; Stephen M Hewitt; Hong Lou; Tracy Lau; Stephanie Ma; Thanh Huynh; Robert A Wesley; Irene O Ng; Karel Pacak; Ronnie T Poon; Y Peng Loh
Journal:  J Clin Invest       Date:  2011-03       Impact factor: 14.808

2.  Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors.

Authors:  Hazem Abdelkarim; Raghupathi Neelarapu; Antonett Madriaga; Aditya S Vaidya; Irida Kastrati; Bhargava Karumudi; Yue-Ting Wang; Taha Y Taha; Gregory R J Thatcher; Jonna Frasor; Pavel A Petukhov
Journal:  ChemMedChem       Date:  2017-11-30       Impact factor: 3.466

Review 3.  Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.

Authors:  S Spiegel; S Milstien; S Grant
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

4.  Novel (64)Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases.

Authors:  Qingqing Meng; Feng Li; Sheng Jiang; Zheng Li
Journal:  ACS Med Chem Lett       Date:  2013-07-25       Impact factor: 4.345

5.  Biological evaluation of new largazole analogues: alteration of macrocyclic scaffold with click chemistry.

Authors:  Xianlin Li; Zhenchao Tu; Hua Li; Chunping Liu; Zheng Li; Qiao Sun; Yiwu Yao; Jinsong Liu; Sheng Jiang
Journal:  ACS Med Chem Lett       Date:  2012-12-05       Impact factor: 4.345

6.  LSD1 Substrate Binding and Gene Expression Are Affected by HDAC1-Mediated Deacetylation.

Authors:  Dhanusha A Nalawansha; Mary Kay H Pflum
Journal:  ACS Chem Biol       Date:  2016-12-15       Impact factor: 5.100

7.  Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.

Authors:  Jing-Ping Liou; Shiow-Lin Pan; Che-Ming Teng; Chun-Han Chen; Mei-Chuan Chen; Jing-Chi Wang; An-Chi Tsai; Ching-Shih Chen
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

8.  Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.

Authors:  Sridurga Mithraprabhu; Anna Kalff; Annie Chow; Tiffany Khong; Andrew Spencer
Journal:  Epigenetics       Date:  2014-11       Impact factor: 4.528

Review 9.  Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.

Authors:  Jian-Jun Gao; Zhen-Yan Shi; Ju-Feng Xia; Yoshinori Inagaki; Wei Tang
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

10.  Hepatocellular tumors: immunohistochemical analyses for classification and prognostication.

Authors:  Regina Cheuk-Lam Lo; Irene Oi-Lin Ng
Journal:  Chin J Cancer Res       Date:  2011-12       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.